AB Corporate Bond ETF (NASDAQ:EYEG) Stock Passes Above Fifty Day Moving Average – Here’s What Happened

AB Corporate Bond ETF (NASDAQ:EYEG)’s share price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $35.26 and traded as high as $35.29. AB Corporate Bond ETF shares last traded at $35.2240, with a volume of 17 shares trading hands.

AB Corporate Bond ETF Trading Up 0.4%

The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.07. The company has a 50 day simple moving average of $35.26 and a two-hundred day simple moving average of $35.59. The firm has a market cap of $28.18 million, a PE ratio of -20.97 and a beta of 0.17.

AB Corporate Bond ETF Increases Dividend

The business also recently announced a monthly dividend, which was paid on Thursday, June 4th. Stockholders of record on Monday, June 1st were paid a $0.1415 dividend. The ex-dividend date was Monday, June 1st. This is a positive change from AB Corporate Bond ETF’s previous monthly dividend of $0.14. This represents a c) dividend on an annualized basis and a dividend yield of 4.8%. AB Corporate Bond ETF’s dividend payout ratio (DPR) is currently -102.98%.

Institutional Trading of AB Corporate Bond ETF

A number of hedge funds have recently modified their holdings of EYEG. Wealth Enhancement Advisory Services LLC boosted its stake in shares of AB Corporate Bond ETF by 32.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock worth $5,634,000 after buying an additional 38,685 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of AB Corporate Bond ETF by 166.7% in the fourth quarter. Jane Street Group LLC now owns 15,741 shares of the specialty pharmaceutical company’s stock worth $563,000 after buying an additional 9,839 shares during the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in shares of AB Corporate Bond ETF in the fourth quarter worth about $34,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

About AB Corporate Bond ETF

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.